A single agreement ignited a rally in pharmaceutical stocks Tuesday, with industry giant Pfizer (NYSE: PFE) becoming the star performer on Wall Street. Its shares surged nearly 7% intraday, propelled by a “historic” deal with the Trump administration where the company pledged to lower drug prices in exchange for a three-year tariff exemption and a commitment to invest approximately $70 billion in U.S. manufacturing.
U.S. stock indexes posted modest gains, led by strength in the healthcare and industrial sectors. Trading volume for Pfizer was exceptionally active, with over 153 million shares changing hands—more than 3.5 times its three-month average volume of 43.3 million. Other major pharma peers also climbed: Johnson & Johnson (NYSE: JNJ) rose 2.09% to $185.42, while Eli Lilly (NYSE: LLY) advanced 5.02% to $763.00.
The direct catalyst for Pfizer’s sharp rally was the milestone agreement. According to details reported by The Washington Post, the deal has three key components:
This round of price negotiations stems from an executive order signed by President Trump in May. The order directed the government to renegotiate pricing with domestic drugmakers to ensure Americans pay no more than patients in other wealthy nations.
” We pay much higher for drugs than the rest of the world. We subsidize the rest of the world [and] we’re not doing that anymore,” Trump complained publicly last week. The policy outlined a two-step approach: voluntary price cuts first, with the implication of mandatory cuts to follow. Pfizer evidently chose the former, aiming to retain more control over its pricing and, to some extent, protect its profit margins.
While the market reacted positively to the news, analysts caution that the long-term financial impact of the deal remains to be seen. The key question is whether the revenue loss from price concessions will be offset by expanded production scale, potential volume growth, and the tariff exemption.
From an investment perspective, Pfizer’s current valuation appears attractive: it trades at just 12.6 times trailing earnings and an even lower price-to-free-cash-flow ratio of 10.9. If the company can leverage this opportunity to become a preferred provider for Medicaid and improve its standing with regulators, it could potentially kick-start a new growth engine.
